NC TraCS Institute logo

A statewide network to help detect cardiovascular disease risk

Samuel Cykert, MD

Samuel Cykert, MD, from the University of North Carolina at Chapel Hill, and colleagues created a statewide network of health care professionals in 219 small primary care practices. Researchers examined existing electronic health records for 345,440 patients. They used an estimation methodology including data from the 236,925 patients who had cholesterol numbers in their electronic health records to determine the risk for developing cardiovascular disease among the 108,515 patients lacking cholesterol scores.

The researchers found that using the formal imputation method based on other available indicators, such as smoking status, hypertension, weight, diabetes status, and gender, 43,205 patients with missing cholesterol values were identified with atherosclerotic cardiovascular disease risk scores ≥10 percent versus 40,565 with risk scores ≥10 percent identified using the "good value" methodology, which inserts conservative values for missing total cholesterol (170 mg/dl) and high-density lipoprotein cholesterol (50 mg/dl). The formal imputation method yielded a lower specificity and a higher false-positive rate than the conservative estimates used in the good value methodology.

"Whether doctors are part of a large health system or in a small rural practice, the fact that all these patients have digital data now means we can identify patients who are at high risk of developing a very serious condition without waiting six months for them to make an appointment," Cykert said in a statement. "Doctors can engage with these patients immediately and re-engage with them as needed to decrease risk, which is so crucial when it comes to decreasing the number of heart attacks and strokes."

More information: Abstract/Full Text

Originally published at

The lone scientist problem, and how two Carolina professors are addressing it

Robert Hummer - UNC, talks to course participants
Robert Hummer, a Howard W. Odum Distinguished Professor of Sociology and fellow at the Carolina Population Center, teaches a course on how to integrate the social and biological sciences on November 12, 2018, on the campus of the University of North Carolina at Chapel Hill.
(Johnny Andrews/UNC-Chapel Hill)

Two Carolina professors are combining their distinct areas of expertise to help students address some of the toughest health issues of our time.

Good science is a team sport — especially when it comes to addressing health disparities.

That's the foundation of a new UNC-Chapel Hill research training program that challenges students to explore both the biological and social factors that influence health in the United States.

Led by sociologist Robert Hummer and epidemiologist Allison Aiello, the Biosocial Training Program funds seven graduate and post-doctoral students this year as they study some of the most pressing health issues of our time. The program, funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is housed in the Carolina Population Center.

"This kind of work can't just be done by a single person," Hummer said. "People can't sit under trees and think big thoughts and produce great science. That's not how it works anymore. You have to have training across disciplines."

Continue Reading

Breakthrough peanut allergy study conducted at the CTRC

Successful Peanut Allergy Clinical Trial Results Published in NEJM

The treatment, AR101 from Aimmune Therapeutics, was based on research conducted in the lab of Wesley Burks, MD. It significantly increased the amount of peanut protein tolerated. UNC's Edwin Kim, MD, MS, was PI at the UNC site of this international trial.

CHAPEL HILL, NC – Aimmune Therapeutics, Inc., a California-based biopharmaceutical company developing treatments for potentially life-threatening food allergies, published in the New England Journal of Medicine its full results of the landmark phase 3 PALISADE clinical trial of AR101, an investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. PALISADE is the largest and first successful phase 3 peanut allergy immunotherapy trial to date.

A. Wesley Burks, MD
A. Wesley Burks, MD

"This paper recognizes the rigor, scale and importance of the PALISADE trial, which will inform ongoing research in food allergy and could change practice for peanut allergy," said senior author A. Wesley Burks, MD, Executive Dean and Curnen Distinguished Professor of Pediatrics at the University of North Carolina School of Medicine, and member of the Aimmune Scientific Advisory Board. "Peanut allergy demands lifelong vigilance to avoid accidental exposures, and the unpredictable severity of reactions that do occur can take a toll on children and families. By significantly reducing the frequency and severity of allergic reactions to peanut, AR101 could provide reassurance and make a meaningful, beneficial impact on people's daily lives."

Continue Reading

TraCS partner RTI leads study to advance research through free and expanded newborn screening

Cynthia M. Powell, MD, professor of pediatrics and genetics in the UNC School of Medicine, is Early Check Lead Investigator for the team from UNC.

Cynthia M. Powell, MD

RESEARCH TRIANGLE PARK, NC -- Early Check, a new research study, led by RTI International and a group of distinguished partners, is now available for newborn babies in North Carolina. Early Check is a free screening study designed to identify children with rare health conditions before symptoms appear and will study the benefits of early treatments. New and expectant mothers may enroll in the program online from their second trimester until 4 weeks after their child's birth.

"We are enrolling participants now and hope to offer every baby born in North Carolina the opportunity to participate in this unique study," said Don Bailey, PhD, Distinguished Fellow at RTI International and principal investigator for Early Check.

Currently, the North Carolina State Laboratory of Public Health performs newborn screening for all babies born in the state. Early Check staff located in the NC state Lab will perform the additional Early Check screenings. "The North Carolina State Laboratory of Public Health is excited to be advancing the science of public health through our partnership with RTI," said Scott J. Zimmerman, DrPH, MPH, director of the North Carolina State Laboratory of Public Health.

Continue Reading

Know any news related to Translational & Clinical Research?
Share a Story

Media Contact:

Michelle Maclay, Communications Director